تاريخ الإيرادات والأرباح والتدفقات النقدية من القوائم المالية الرسمية.
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
الرسوم البيانية التفاعلية والقوائم الكاملة ← نموذج التقييم (DCF) ←
| قائمة الدخل | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| إجمالي الإيرادات | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B | $2.1B | $2.2B | $2.2B | $2.1B | $1.9B | $1.7B | $1.6B | $2.0B | $1.8B | $1.5B |
| إجمالي الربح | $1.5B | $1.5B | $1.3B | $1.3B | $1.8B | $2.3B | $2.0B | $1.3B | $1.3B | $1.0B | $972M | $930M | $971M | $940M | $924M | $824M | $740M | $699M | $835M | $715M | $623M |
| هامش الربح الإجمالي % | 52.1% | 53.1% | 48.0% | 48.1% | 53.2% | 59.6% | 52.6% | 44.8% | 45.0% | 45.6% | 46.0% | 44.2% | 43.4% | 43.4% | 43.7% | 42.9% | 43.4% | 45.1% | 42.6% | 40.0% | 40.3% |
| الدخل التشغيلي (EBIT) | $358M | $357M | $411M | $399M | $781M | $1.3B | $1.0B | $405M | $371M | $305M | $306M | $267M | $230M | $259M | $201M | $118M | $173M | $140M | $201M | $175M | $152M |
| هامش التشغيل % | 12.3% | 12.5% | 14.9% | 14.5% | 23.6% | 35.0% | 27.0% | 14.1% | 13.4% | 13.5% | 14.4% | 12.7% | 10.3% | 11.9% | 9.5% | 6.1% | 10.1% | 9.0% | 10.3% | 9.8% | 9.8% |
| صافي الدخل | $238M | $242M | $296M | ($118M) | $569M | $943M | $728M | $228M | $239M | $113M | $234M | $212M | $158M | $168M | $68M | $1M | $384M | $86M | $128M | $133M | $117M |
| هامش الربح الصافي % | 8.2% | 8.5% | 10.7% | -4.3% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 5.0% | 11.1% | 10.1% | 7.1% | 7.8% | 3.2% | 0.1% | 22.5% | 5.5% | 6.6% | 7.4% | 7.6% |
| EBITDA | — | $663M | $840M | $714M | $1.2B | $1.6B | $1.2B | $515M | $505M | $446M | $386M | $352M | $323M | $332M | $223M | $200M | $267M | $201M | $263M | $245M | $229M |
| ربحية السهم (EPS) | $2.09 | $2.13 | $2.41 | $-0.95 | $4.50 | $8.08 | $6.50 | $2.04 | $2.14 | $1.02 | $2.12 | $1.87 | $1.39 | $1.48 | $0.60 | $0.01 | $3.25 | $0.73 | $1.08 | $1.10 | $0.93 |
| الأسهم القائمة (م) | — | 113M | 123M | 125M | 126M | 117M | 112M | 112M | 112M | 111M | 110M | 113M | 114M | 114M | 115M | 114M | 118M | 117M | 119M | 121M | 126M |
المصدر: التقارير العامة للشركة (SEC). تحقق من SEC EDGAR قبل الاعتماد على أي رقم.
الميزانيات والتدفقات النقدية والبيانات الفصلية والنسب المالية الكاملة في العارض التفاعلي لـ RVTY. /companies/us/RVTY
المعلومات في هذا الموقع لأغراض تعليمية وإعلامية فقط ولا تشكل نصيحة استثمارية. لا تُنشر أسعار مستهدفة أو توصيات.
About TickerBase · Data methodology & sources · Privacy · Terms